ARIKAYCE liposomal 590 mg nebuliser dispersion

DRUG2 trials

Sponsors

Insmed Inc., Centre Hospitalier Universitaire Amiens Picardie

Conditions

"Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC)"Mycobacterium xenopi pulmonary infection

Phase 3

ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC)

CompletedCTIS2023-505273-33-00

Insmed Inc."Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC)"

Start: 2021-02-15End: 2025-12-16Target: 383Updated: 2025-06-20

AKAPI: Amikacin Liposome Inhalation Suspension for treatment of Mycobacterium xenopi pulmonary infection: A prospective controlled open-label randomized study

RecruitingCTIS2023-506843-40-00

Centre Hospitalier Universitaire Amiens PicardieMycobacterium xenopi pulmonary infection

Start: 2025-10-29Target: 190Updated: 2025-10-24